期刊
TRANSPLANTATION AND CELLULAR THERAPY
卷 28, 期 10, 页码 657-666出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2022.07.008
关键词
-
资金
- National Institutes of Health [R01 CA168814, R21 HL139934, R01 CA264921, R01 HL158096]
Hematopoietic cell transplantation is a potentially curative treatment for hematologic and nonhematologic disorders. Graft-versus-host disease is a major complication post-transplantation, and biomarkers play a significant role in disease diagnosis and management.
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for many hematologic and nonhematologic disorders. Graft-versus-host-disease (GVHD) in its acute or chronic form remains the most important nonrelapse post-HCT complication. Biomarkers offer objective, unbiased information on systemic disorders, and significant attention has focused on identifying biomarkers for GVHD. Ideally, a GVHD biomarker is actionable, with the results of biomarker testing used to guide clinical management of disease and clinical trial design. Although many GVHD biomarkers have been identified, none have been properly qualified for clinical use. The National Institutes of Health (NIH) and Food and Drug Administration (FDA) have provided biomarker subtype definitions; however, confusion remains about the proper definition and application of these subtypes in the HCT field. The 2014 NIH consensus development project provided a framework for the development of biomarkers for clinical practice. This review aims to clarify the biomarker subtype definitions and reemphasize the developmental framework. Armed with this knowledge, clinicians can properly translate GVHD biomarkers for clinical use. (C) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据